Partner With Us NRI

Thyrocare Technologies Ltd share Price

Company details

6M Return 23.41%
1Y Return -17.91%
Mkt Cap.(Cr) 2,977.05
Volume 42,818
Div Yield 3.19%
OI Chg %
Volume 42,818

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services firm Thyrocare Technologies declares Q4FY22 result:

  • Revenue from operations of Rs. 562 Crore, grown by 18% YoY. Revenue for the final quarter of the year of Rs. 123 Crore, grown by 12% in sequential quarters mainly with revival of the base non covid business. Revenue from COVID business was flat in sequential quarters despite of 3rd wave in January. Non Covid business however revived significantly and surpassed the pre-COVID business. Continued focus on B2B business enabled us to garner lost volumes. Revenue and volumes for the month of March were all time high
  • Gross margin for the year improved mainly on account of reduction in the covid reagent/ consumables, however to enable growth aggressive prices are offered in the last quarter on routine non aarogyam tests and certain aarogyam profiles that has lead to impact on Q4 gross margins which shall settle down in the coming period.
  • Absolute EBITDA of Rs. 231 crore, grown by 35% YoY, mainly on account of better EBITDA margins on account of lower reagent/ consumable and operations cost in Government COVID business. The EBITDA margin at 41% for the year were tampered down in the last two quarters mainly on account of impact on the topline due to erosion of high margin government contract business, aggressive discounts to the network on some routine tests/ profiles to revive the business, spendings on manpower in particular growth teams to sustain growth and infrastructure to improve turnaround time to the patients.
  • 4.40 million COVID RTPCR tests were performed in the year, though despite 3 rd wave in January only 0.41 million were performed in the last quarter, thereby the focus is now shifted to non COVID segment.
  • Total 21.07 million samples (including COVID) sourced from 16.32 million patients (including COVID) were processed during current year.
  • 110.30 million tests were processed in the current year that includes standalone tests, COVID tests and tests included in the preventive care Aarogyam profiles.
  • Pathology business grew by 12% in sequential quarter and yearly by 18%. Growth in the current quarter was mainly on account of revival of B2B non COVID business
  • Radiology business accounted for about 5% of reported consolidated revenue of Thyrocare Group revived significantly after complete shut down for couple of months in covid and thereafter out of the impact of lockdowns, posting 34% YOY growth in the current year
  • Consolidated annual revenue of the group grew by 19% YOY, with positive signs of revival in non covid business. COVID business significantly eroded in last two quarters and radiology business growing at pre COVID level.




Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Thyrocare Technologies Ltd Stocks COMPARISION


Equity Capital: 515.38 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 18,676.55 -6,386.02
LAST 3M 37,244.98 6,086.45
LAST 6M 47,342.46 153,492.54
LAST 12M 133,811.11 156,210.35

Thyrocare Technologies Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
Registered Address

D-37/1 TTC Industrial Area, MIDC Turbhe, Navi Mumbai, Maharashtra, 400703

Tel : 91-22-27622762
Email : investor_relations:thyrocare.com
Website : http://www.thyrocare.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 539871
Book Closure Date (Month) :
BSE Group : A
ISIN : INE594H01019

FAQ’s on Thyrocare Technologies Ltd Shares

You can buy Thyrocare Technologies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Thyrocare Technologies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 22, 2023 03:58 PM the closing price of Thyrocare Technologies Ltd was ₹ 562.45.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 22, 2023 03:58 PM, the market cap of Thyrocare Technologies Ltd stood at ₹ 2,977.05.

The latest PE ratio of Thyrocare Technologies Ltd as of Sep 22, 2023 03:58 PM is 49.68

The latest PB ratio of Thyrocare Technologies Ltd as of Sep 22, 2023 03:58 PM is 0.17

The 52-week high of Thyrocare Technologies Ltd is ₹ 768.25 while the 52-week low is ₹ 415.40

Download Our App

market app
market app